Comparative Pharmacology
Head-to-head clinical analysis: ZERIT XR versus ZIAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZERIT XR versus ZIAGEN.
ZERIT XR vs ZIAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ZERIT XR (stavudine extended-release) is a nucleoside analog reverse transcriptase inhibitor (NRTI). It is phosphorylated intracellularly to stavudine triphosphate, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HIV-1 reverse transcriptase.
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI). It is converted intracellularly to carbovir triphosphate, which competes with dGTP for incorporation into viral DNA, causing chain termination and inhibition of HIV reverse transcriptase.
ZERIT XR (stavudine extended-release) is administered orally once daily. Adult dose: 100 mg once daily for patients ≥60 kg; 75 mg once daily for patients <60 kg.
600 mg orally once daily, or 300 mg orally twice daily.
None Documented
None Documented
5.7 hours (range 4–8 hours) in patients with normal renal function; prolonged to 13–20 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 1.5–2 hours (mean 1.7 h); intracellular triphosphate half-life: 12–15 hours, supporting once-daily dosing
Approximately 94% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; <1% is eliminated in feces.
Renal (approximately 82% as unchanged drug and metabolites via glomerular filtration and active tubular secretion); biliary/fecal (minor, <2%)
Category C
Category C
Antiretroviral (NRTI)
Antiretroviral (NRTI)